Immunoglobulin G4-Kappa, Anti-(Human Adp-Ribosyl Cyclase/Cyclic Adp-Ribose Hydrolase 1 (Ec:3.2.2.6) (Adprc 1/Cadrp Hydrolase 1, Cell Surface Antigen Cd38)), Humanized Monoclonal Antibody, Fused At Each C-Terminus Of The Heavy Chains (1-447, 1''-447'') To Attenuated Human Interferon .Alpha.-2B (Ifn.Alpha.2B) Variant (K23>R470, T106>A553, A145>D592) (448-612, 448''-612''); Gamma4 Heavy Chain Humanized Fused To Ifn.Alpha.2B (1-612) (Vh (Homo Sapiens Ighv1-69-2*01 (90.7%)-(Ighd)-Ighj4*01 (85.7%)) Cdrimgt (8.8.13) (26-33.51-58.97-109) (1-120)-Homo Sapiens Ighg4*01, G4V5 H P10 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 (231-340), Ch3 (341-445), Chs (446-447))(121-447), Fused To Ifn.Alpha.2B K23>R (470), T106>A (553), A145>D (592) (448-612)),(134-214')-Disulfide With Kappa Light Chain Humanized (1'-214') (V-Kappa (Homo Sapiens Igkv1-33*01 (83.2%)-Igkj4*01 (100%)) Cdr-Imgt (6.3.9) (27-32.50-52.89-97) (1'-107')-Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')); Dimer (226-226'':229-229'')-Bisdisulfide; Produced In Chinese Hamster Ovary (Cho) K1Sv Cells, Glycoform Alfa
Neoplasm
Explore 889 assets in Neoplasm →Floatz Rating
D24/100
Confidence
Indicative
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
11Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04157517CT.gov A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4-Kappa, Anti-(Human Adp-Ribosyl Cyclase/Cyclic Adp-Ribose Hydrolase 1 (Ec:3.2.2.6) (Adprc 1/Cadrp Hydrolase 1, Cell Surface Antigen Cd38)), Humanized Monoclonal Antibody, Fused At Each C-Terminus Of The Heavy Chains (1-447, 1''-447'') To Attenuated Human Interferon .Alpha.-2B (Ifn.Alpha.2B) Variant (K23>R470, T106>A553, A145>D592) (448-612, 448''-612''); Gamma4 Heavy Chain Humanized Fused To Ifn.Alpha.2B (1-612) (Vh (Homo Sapiens Ighv1-69-2*01 (90.7%)-(Ighd)-Ighj4*01 (85.7%)) Cdrimgt (8.8.13) (26-33.51-58.97-109) (1-120)-Homo Sapiens Ighg4*01, G4V5 H P10 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 (231-340), Ch3 (341-445), Chs (446-447))(121-447), Fused To Ifn.Alpha.2B K23>R (470), T106>A (553), A145>D (592) (448-612)),(134-214')-Disulfide With Kappa Light Chain Humanized (1'-214') (V-Kappa (Homo Sapiens Igkv1-33*01 (83.2%)-Igkj4*01 (100%)) Cdr-Imgt (6.3.9) (27-32.50-52.89-97) (1'-107')-Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')); Dimer (226-226'':229-229'')-Bisdisulfide; Produced In Chinese Hamster Ovary (Cho) K1Sv Cells, Glycoform Alfa (this asset) | Teva Branded Pharmaceutical Products R&D LLC | P1/2 | D · 24 |
| Panitumumab | Astellas Pharma Inc | P2 | BB |
| Irinotecan | Mirati Therapeutics Inc. | P4 | BB |
| Nivestim | Ankara Etlik City Hospital | P2 | BB |
| Dexasone | Hellenic Society of Hematology | P3 | BB |
| Feladilimab | GlaxoSmithKline | P2 | BB |
| Carboplatin | Bristol-Myers Squibb | P3 | BB |
| Pralsetinib, Trans- | Seoul National University Bundang Hospital | P3 | BB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Immunoglobulin G4-Kappa, Anti-(Human Adp-Ribosyl Cyclase/Cyclic Adp-Ribose Hydrolase 1 (Ec:3.2.2.6) (Adprc 1/Cadrp Hydrolase 1, Cell Surface Antigen Cd38)), Humanized Monoclonal Antibody, Fused At Each C-Terminus Of The Heavy Chains (1-447, 1''-447'') To Attenuated Human Interferon .Alpha.-2B (Ifn.Alpha.2B) Variant (K23>R470, T106>A553, A145>D592) (448-612, 448''-612''); Gamma4 Heavy Chain Humanized Fused To Ifn.Alpha.2B (1-612) (Vh (Homo Sapiens Ighv1-69-2*01 (90.7%)-(Ighd)-Ighj4*01 (85.7%)) Cdrimgt (8.8.13) (26-33.51-58.97-109) (1-120)-Homo Sapiens Ighg4*01, G4V5 H P10 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 (231-340), Ch3 (341-445), Chs (446-447))(121-447), Fused To Ifn.Alpha.2B K23>R (470), T106>A (553), A145>D (592) (448-612)),(134-214')-Disulfide With Kappa Light Chain Humanized (1'-214') (V-Kappa (Homo Sapiens Igkv1-33*01 (83.2%)-Igkj4*01 (100%)) Cdr-Imgt (6.3.9) (27-32.50-52.89-97) (1'-107')-Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')); Dimer (226-226'':229-229'')-Bisdisulfide; Produced In Chinese Hamster Ovary (Cho) K1Sv Cells, Glycoform Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P1/2 | D · 26 |
| Melanoma | — | P1/2 | D · 24 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4-Kappa, Anti-(Human Adp-Ribosyl Cyclase/Cyclic Adp-Ribose Hydrolase 1 (Ec:3.2.2.6) (Adprc 1/Cadrp Hydrolase 1, Cell Surface Antigen Cd38)), Humanized Monoclonal Antibody, Fused At Each C-Terminus Of The Heavy Chains (1-447, 1''-447'') To Attenuated Human Interferon .Alpha.-2B (Ifn.Alpha.2B) Variant (K23>R470, T106>A553, A145>D592) (448-612, 448''-612''); Gamma4 Heavy Chain Humanized Fused To Ifn.Alpha.2B (1-612) (Vh (Homo Sapiens Ighv1-69-2*01 (90.7%)-(Ighd)-Ighj4*01 (85.7%)) Cdrimgt (8.8.13) (26-33.51-58.97-109) (1-120)-Homo Sapiens Ighg4*01, G4V5 H P10 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 (231-340), Ch3 (341-445), Chs (446-447))(121-447), Fused To Ifn.Alpha.2B K23>R (470), T106>A (553), A145>D (592) (448-612)),(134-214')-Disulfide With Kappa Light Chain Humanized (1'-214') (V-Kappa (Homo Sapiens Igkv1-33*01 (83.2%)-Igkj4*01 (100%)) Cdr-Imgt (6.3.9) (27-32.50-52.89-97) (1'-107')-Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')); Dimer (226-226'':229-229'')-Bisdisulfide; Produced In Chinese Hamster Ovary (Cho) K1Sv Cells, Glycoform Alfa in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-kappa-anti-human-adp-ribosyl-cyclasecyclic-adp-ribose-hydrolase-1-ec3226-adprc-1cadrp-hydrolase-1-cell-surface-antigen-cd38-humanized-monoclonal-antibody-fused-at-each-c-terminus-of-the-heavy-chains-1-447-1-447-to-attenuated-human-interferon-alpha-2b-ifnalpha2b-variant-k23r470-t106a553-a145d592-448-612-448-612-gamma4-heavy-chain-humanized-fused-to-ifnalpha2b-1-612-vh-homo-sapiens-ighv1-69-201-907-ighd-ighj401-857-cdrimgt-8813-26-3351-5897-109-1-120-homo-sapiens-ighg401-g4v5-h-p10-ch1-121-218-hinge-1-12-s10p-228-219-230-ch2-231-340-ch3-341-445-chs-446-447121-447-fused-to-ifnalpha2b-k23r-470-t106a-553-a145d-592-448-612134-214-disulfide-with-kappa-light-chain-humanized-1-214-v-kappa-homo-sapiens-igkv1-3301-832-igkj401-100-cdr-imgt-639-27-3250-5289-97-1-107-homo-sapiens-igkc01-100-km3-a451-153-v101-191-108-214-dimer-226-226229-229-bisdisulfide-produced-in-chinese-hamster-ovary-cho-k1sv-cells-glycoform-alfa-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →